Journals / Journal of Contemporary Medicine / 2022 / Cilt: 12 - Sayı: 5

Role of Hematological Parameters in Systemic Sclerosis Patients with Pulmonary System Involvement

Pulmoner Tutulumu Olan Sistemik Skleroz Hastalarında Hematolojik Parametrelerin Rolü

Pages
608–616
Publication Date
2022-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: RPR can be used as screening parameters for PH in ILD associated with SSc.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Systemic sclerosis (SSc) is an autoimmune disease characterized by generalized micro and macroangiopathy.
📊
Key Findings & Data:Results: ILD was found to be associated with high red cell distribution width (RDW) and erythrocyte sedimentation rate, independent of PH.
💡
Conclusion & Impact:Conclusion: RPR can be used as screening parameters for PH in ILD associated with SSc.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:interstisyel akciğer hastalığı · pulmoner hipertansiyon · sistemik skleroz

Abstract

Aim: Systemic sclerosis (SSc) is an autoimmune disease characterized by generalized micro and macroangiopathy. Mortality in SSc is primarily due to pulmonary complications. This study was aimed to reveal the relationship between parenchymal and vascular involvements of the pulmonary system and hematological parameters in patients with SSc. Material and Method: Participants were divided into three groups: both interstitial lung disease (ILD) and pulmonary hypertension (PH), those with only ILD and those with neither ILD nor PH. Laboratory data were compared between these groups. Results: ILD was found to be associated with high red cell distribution width (RDW) and erythrocyte sedimentation rate, independent of PH. The platelet (PLT) count was significantly lower, and the RDW to PLT ratio (RPR) level was significantly higher in those with ILD and PH coexistence compared to those with only ILD. Conclusion: RPR can be used as screening parameters for PH in ILD associated with SSc.

Özet

Amaç: Sistemik skleroz (SSc), mikro ve makroanjiyopati ile karakterize otoimmun bir hastalıktır. SSc'deki mortalite esas olarak pulmoner komplikasyonlara bağlıdır. Bu çalışma, SSc hastalarının vasküler ve parankimal pulmoner tutulumları ile hematolojik parametreler arasındaki ilişkiyi ortaya koymayı amaçladı. Gereç ve Yöntem: Katılımcılar, SSc tanılı interstisyel akciğer hastalığı (İAH) ile birlikte pulmoner hipertansiyonu (PH) olanlar, sadece İAH'si olanlar ve İAH ve PH'si olmayan hastalar olmak üzere üç gruba ayrıldı. Laboratuvar verileri bu gruplar arasında karşılaştırıldı Bulgular: İAH'nIn PH'dan bağımsız olarak yüksek kırmızı hücre dağılım genişliği (RDW) ve eritrosit sedimantasyon hızı ile ilişkili olduğu bulundu. Trombosit (PLT) sayısı anlamlı olarak daha düşüktü ve RDW / PLT oranı (RPO) seviyesi İAH ve PH birlikteliği olanlarda sadece İAH olanlara göre anlamlı olarak daha yüksekti. Sonuç: RPR, SSc ile ilişkili İAH'da PH için tarama parametreleri olarak kullanılabilir.

🔖

Cite This Article

TEZCAN, D., TURAN, Ç., HAKBİLEN, S., YİLMAZ, S. (2022). Role of Hematological Parameters in Systemic Sclerosis Patients with Pulmonary System Involvement. Journal of Contemporary Medicine, Cilt: 12 - Sayı: 5, 608–616. https://ajindex.com/articles/774767

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Asano Y. Systemic sclerosis. J Dermatol 2018;45:128-38.
  2. Singh D, Parihar AK, Patel S, et al. Scleroderma: An insight into causes, pathogenesis and treatment strategies. Pathophysiology 2019;26:103-14.
  3. Wielosz E, Majdan M. Clinical and serological diversity in systemic sclerosis. Wiad Lek 2018;71:78-83.
  4. Amoda O, Ravat V, Datta S, et al. Trends in demographics, hospitalization outcomes, comorbidities, and mortality risk among systemic sclerosis patients. Cureus 2018;10:e2628. Rubio-Rivas M, Homs NA, Cuartero D, et al. The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis:Systematic review and meta-analysis. Autoimmun Rev 2021;20:102713. Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 2020;55:1902026.
  5. Harari S, Elia D, Humbert M. Pulmonary hypertension in parenchymal lung diseases:any future for new therapies? Chest 2018;153:217–23.
  6. Chauvelot L, Gamondes D, Berthiller J,et al. Hemodynamic response to treatment and outcomes in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis: data from a study identifying prognostic factors in pulmonary hypertension associated with interstitial lung disease. Arthritis Rheumatol 2021;73:295-304.
  7. Volkmann ER, Saggar R, Khanna D, et al. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. Arthritis Rheumatol 2014;66:1900-8.
  8. Le Pavec J, Girgis RE, Lechtzin N, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease:impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011;63:2456-64.
  9. Young A, Vummidi D, Visovatti S, et al. Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis. Arthritis Rheumatol 2019;71:1339-49.
  10. Weatherald J, Montani D, Jevnikar M, et al. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2019;28:190023. Yayla ME, İlgen U, Okatan İE, et al. Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis. Clin Rheumatol 2020;39:77-83.
  11. Farkas N, Szabó A, Lóránd V, et al. Clinical usefulness of measuring red blood cell distribution width in patients with systemic sclerosis. Rheumatology (Oxford) 2014;53: